Fabry Disease Market

Global Fabry Disease Market Size (2023 to 2028)

The global market size for Fabry disease is estimated to be growing at a CAGR of 5.98% from 2023 to 2028 and will be worth USD 1069.1 million by 2028 from USD 799.7 million in 2023.

Fabry disease is a rare genetic disorder caused by a lysosomal enzyme called -galactosidase that is inactive. A (-Gal A) causes glycosphingolipid (fat) metabolism to malfunction. A patient's alpha-galactosidase enzyme deficiency leads to gradual organ failure.  The lysosomal enzyme is in charge of breaking down complex sugar-lipid polymers known as glycolipids and digesting specific substances. This enzyme deficiency can cause cell abnormalities and organ system failure, especially in small blood arteries, the heart, and the kidneys.

Impact of COVID-19 on the global Fabry disease market:

The impact of COVID-19 on Fabry disease patients receiving enzyme replacement therapy is uncertain. Several individuals receiving hospital care had their infusions interrupted due to fear of infection. The effects of temporary treatment interruption have been studied in more depth in other lysosomal storage diseases, but resuming therapy does not entirely reverse clinical deterioration caused by the temporary interruption. When enzyme replacement therapy is required during a pandemic, home therapy appears to be the most effective strategy to maintain access. Throughout the forecast period, these factors are anticipated to fuel the growth of the Fabry disease market. Patients with Fabry disease will be able to obtain regular medication if coronavirus infections are appropriately managed in hospitals and other healthcare settings, supporting the market's rise in the near future.

MARKET DRIVERS:

Factors such as global healthcare infrastructure development and favorable reimbursement and financial support policies in developed nations are likely to drive the expansion of the global Fabry disease market.

The ongoing research operations and the implementation of advanced technology in these initiatives are boosting the market's growth significantly. In addition, several prominent regulatory authorities have recently approved innovative treatments for the condition. During the forecast period, the development and approval of such treatments are also predicted to accelerate market expansion. The emergence of pharmaceuticals used in the treatment of risk associated with Fabry illness and the rise in the strategic partnership and licensing arrangement between the firms are some of the essential reasons driving the Fabry disease drug market expansion, among others.

Patients with Fabry disease frequently experience strokes, excruciating pain, early heart condition, and impaired kidney function, leading to kidney failure and disabling gastrointestinal symptoms. Because there is no cure for Fabry disease, treatment focuses on managing problems associated with disease progression and providing symptomatic relief. Various people are frequently misdiagnosed due to mild symptoms. The global Fabry disease market is expected to rise at a significant rate in the following years due to these factors. Until the patent expires, the researcher or market leader has exclusive distribution rights to the medication. The key leaders will gain the most market share during the forecast period due to the strict supervision of new drugs, which is necessary due to the use of the therapy on a specific population affected by the disease and the limited number of approved drugs due to the associated risks of complications. Furthermore, increased R&D activities and the potential approval of promising pipeline products such as substrate reduction therapies and enzyme replacement therapies, and increased demand from emerging economies will create new opportunities for the Fabry disease drug market to grow during the forecast period.

MARKET RESTRAINTS:

On the other hand, a lack of such diagnostic processes and educated specialists are likely to limit the worldwide Fabry disease market growth significantly. Furthermore, effective treatment is either unavailable or unaffordable. The lack of information about Fabry disease in several developing countries is among the primary factors acting as restraints. Therefore, it will continue to pose a challenge to the Fabry disease drug market during the forecast period. Furthermore, the market's growth in the coming years may be hampered by a lower susceptibility to drug approval following a significant investment.

REPORT COVERAGE:

This research report on the global Fabry disease market has been segmented and sub-segmented based on the treatment, end-user, and region.

Fabry Disease Market – By Treatment:

• Enzyme Replacement Therapy (ERT)
• Chaperone Treatment
• Substrate Reduction Therapy (SRT)

Based on the treatment, the enzyme replacement therapy segment is expected to develop significantly during the forecast period, as it is the only particular treatment for Fabry disease. Furthermore, the effects of this therapy on various organs have been investigated thoroughly, and it has been shown to improve patients' quality of life. In addition, the rising demand for timely diagnosis and increased awareness of Fabry disease in the healthcare community are expected to promote the expansion of the enzyme replacement therapy segment.

Fabry Disease Market – By End-User:

• Hospitals
• Clinics

Based on the end-user, the clinic segment had the largest share in the global Fabry disease market in 2022. ICD-10-CM codes should also include complete healthcare data, which will aid in the establishment of advanced clinical pathways and disease regimens. However, there is currently no disease-modifying medicine on the market for Fabry disease, although there is much room for development in the near future.

Fabry Disease Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Geographically, the North American regional market dominated the Fabry disease market, accounting for the most significant proportion in 2022. The region's market development is aided by increased acceptance of novel therapies, favorable reimbursement policies, and enhanced healthcare services. In addition, as a result of health insurance programs covering health expenditure expenditures, drug companies boost their R&D efforts in uncommon diseases.

Europe is one of the most promising regions worldwide, and it is predicted to be the second-largest market for Fabry disease during the forecast period. The rising government financial support and endeavors for R&D operations to develop efficient treatment procedures are attributed to the market expansion in Europe.

Because of increased government initiatives to strengthen the healthcare sectors in emerging nations such as India and China, the Asia-Pacific region is expected to be the fastest-growing region of the worldwide Fabry disease market during the forecast period. Furthermore, increased consumer awareness of enzyme replacement treatment, rising healthcare expenditure on research & development, and the adoption of technologically advanced medical devices are likely to fuel market expansion in this area over the forecast period.

Due to a lack of awareness about the condition, a weak healthcare sector, low penetration of new technology, and a scarcity of trained labor in Africa, the Middle East and Africa are likely to hold the smallest share of the market. The slow growth of the market in Africa is expected to be driven by increased efforts by government and non-profit organizations to enhance the healthcare sector to provide basic medical amenities to consumers in the region.

KEY MARKET PLAYERS:

Companies playing a notable role in the global Fabry disease market profiled in this report are ISU Abxis Co Ltd., Greenovation Biotech GmbH, Amicus Therapeutics Inc., Avrobio Inc., Shire Plc., Sanofi S.A., Moderna Therapeutics Inc., JCR Pharmaceuticals, Protalix Biotherapeutics Inc. and Idorsia Pharmaceuticals Ltd.

RECENT HAPPENINGS IN THIS MARKET:

• The FDA approved GalafoldTM (migalastat) in 2018 to treat certain adult patients with Fabry disease.